Literature DB >> 23831613

Tubacin prevents neuronal migration defects and epileptic activity caused by rat Srpx2 silencing in utero.

Manal Salmi1, Nadine Bruneau, Jennifer Cillario, Natalia Lozovaya, Annick Massacrier, Emmanuelle Buhler, Robin Cloarec, Timur Tsintsadze, Françoise Watrin, Vera Tsintsadze, Céline Zimmer, Claude Villard, Daniel Lafitte, Carlos Cardoso, Lan Bao, Gaetan Lesca, Gabrielle Rudolf, Françoise Muscatelli, Vanessa Pauly, Ilgam Khalilov, Pascale Durbec, Yehezkel Ben-Ari, Nail Burnashev, Alfonso Represa, Pierre Szepetowski.   

Abstract

Altered development of the human cerebral cortex can cause severe malformations with often intractable focal epileptic seizures and may participate in common pathologies, notably epilepsy. This raises important conceptual and therapeutic issues. Two missense mutations in the sushi repeat-containing protein SRPX2 had been previously identified in epileptic disorders with or without structural developmental alteration of the speech cortex. In the present study, we aimed to decipher the precise developmental role of SRPX2, to have a better knowledge on the consequences of its mutations, and to start addressing therapeutic issues through the design of an appropriate animal model. Using an in utero Srpx2 silencing approach, we show that SRPX2 influences neuronal migration in the developing rat cerebral cortex. Wild-type, but not the mutant human SRPX2 proteins, rescued the neuronal migration phenotype caused by Srpx2 silencing in utero, and increased alpha-tubulin acetylation. Following in utero Srpx2 silencing, spontaneous epileptiform activity was recorded post-natally. The neuronal migration defects and the post-natal epileptic consequences were prevented early in embryos by maternal administration of tubulin deacetylase inhibitor tubacin. Hence epileptiform manifestations of developmental origin could be prevented in utero, using a transient and drug-based therapeutic protocol.

Entities:  

Keywords:  Srpx2; developmental epilepsy; in utero prevention; neuronal migration; tubulin acetylation

Mesh:

Substances:

Year:  2013        PMID: 23831613     DOI: 10.1093/brain/awt161

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  16 in total

Review 1.  Is birth a critical period in the pathogenesis of autism spectrum disorders?

Authors:  Yehezkel Ben-Ari
Journal:  Nat Rev Neurosci       Date:  2015-07-08       Impact factor: 34.870

Review 2.  Malformations of cortical development: clinical features and genetic causes.

Authors:  Renzo Guerrini; William B Dobyns
Journal:  Lancet Neurol       Date:  2014-06-02       Impact factor: 44.182

Review 3.  Insights into the genetic foundations of human communication.

Authors:  Sarah A Graham; Pelagia Deriziotis; Simon E Fisher
Journal:  Neuropsychol Rev       Date:  2015-01-18       Impact factor: 7.444

4.  SRPX2 Enhances the Epithelial-Mesenchymal Transition and Temozolomide Resistance in Glioblastoma Cells.

Authors:  Haitao Tang; Jiaxin Zhao; Liangyu Zhang; Jiang Zhao; Yongzhi Zhuang; Peng Liang
Journal:  Cell Mol Neurobiol       Date:  2015-12-07       Impact factor: 5.046

5.  Inhibiting histone deacetylase 6 partly protects cultured rat cortical neurons from oxygen‑glucose deprivation‑induced necroptosis.

Authors:  Liming Yuan; Zhen Wang; Lihua Liu; Xiaohong Jian
Journal:  Mol Med Rep       Date:  2015-05-13       Impact factor: 2.952

6.  Cytomegalovirus Infection of the Rat Developing Brain In Utero Prominently Targets Immune Cells and Promotes Early Microglial Activation.

Authors:  Robin Cloarec; Sylvian Bauer; Hervé Luche; Emmanuelle Buhler; Emilie Pallesi-Pocachard; Manal Salmi; Sandra Courtens; Annick Massacrier; Pierre Grenot; Natacha Teissier; Françoise Watrin; Fabienne Schaller; Homa Adle-Biassette; Pierre Gressens; Marie Malissen; Thomas Stamminger; Daniel N Streblow; Nadine Bruneau; Pierre Szepetowski
Journal:  PLoS One       Date:  2016-07-29       Impact factor: 3.240

7.  Next-generation DNA sequencing identifies novel gene variants and pathways involved in specific language impairment.

Authors:  Xiaowei Sylvia Chen; Rose H Reader; Alexander Hoischen; Joris A Veltman; Nuala H Simpson; Clyde Francks; Dianne F Newbury; Simon E Fisher
Journal:  Sci Rep       Date:  2017-04-25       Impact factor: 4.379

8.  Local administration of liposomal-based Srpx2 gene therapy reverses pulmonary fibrosis by blockading fibroblast-to-myofibroblast transition.

Authors:  Qi Wang; Juan Liu; Yinan Hu; Ting Pan; Yongjian Xu; Jun Yu; Weining Xiong; Qing Zhou; Yi Wang
Journal:  Theranostics       Date:  2021-05-13       Impact factor: 11.600

9.  Efficient strategy for the molecular diagnosis of intellectual disability using targeted high-throughput sequencing.

Authors:  Claire Redin; Bénédicte Gérard; Julia Lauer; Yvan Herenger; Jean Muller; Angélique Quartier; Alice Masurel-Paulet; Marjolaine Willems; Gaétan Lesca; Salima El-Chehadeh; Stéphanie Le Gras; Serge Vicaire; Muriel Philipps; Michaël Dumas; Véronique Geoffroy; Claire Feger; Nicolas Haumesser; Yves Alembik; Magalie Barth; Dominique Bonneau; Estelle Colin; Hélène Dollfus; Bérénice Doray; Marie-Ange Delrue; Valérie Drouin-Garraud; Elisabeth Flori; Mélanie Fradin; Christine Francannet; Alice Goldenberg; Serge Lumbroso; Michèle Mathieu-Dramard; Dominique Martin-Coignard; Didier Lacombe; Gilles Morin; Anne Polge; Sylvie Sukno; Christel Thauvin-Robinet; Julien Thevenon; Martine Doco-Fenzy; David Genevieve; Pierre Sarda; Patrick Edery; Bertrand Isidor; Bernard Jost; Laurence Olivier-Faivre; Jean-Louis Mandel; Amélie Piton
Journal:  J Med Genet       Date:  2014-08-28       Impact factor: 6.318

10.  In Utero Administration of Drugs Targeting Microglia Improves the Neurodevelopmental Outcome Following Cytomegalovirus Infection of the Rat Fetal Brain.

Authors:  Robin Cloarec; Sylvian Bauer; Natacha Teissier; Fabienne Schaller; Hervé Luche; Sandra Courtens; Manal Salmi; Vanessa Pauly; Emilie Bois; Emilie Pallesi-Pocachard; Emmanuelle Buhler; François J Michel; Pierre Gressens; Marie Malissen; Thomas Stamminger; Daniel N Streblow; Nadine Bruneau; Pierre Szepetowski
Journal:  Front Cell Neurosci       Date:  2018-03-06       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.